MEDINET Co., Ltd.

Tokyo Stock Exchange 2370.T

MEDINET Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 10.96

MEDINET Co., Ltd. Price to Sales Ratio (P/S) is 10.96 on January 14, 2025, a -38.87% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • MEDINET Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 22.20 on March 08, 2024, which is 102.62% above the current Price to Sales Ratio (P/S).
  • MEDINET Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 10.70 on December 24, 2024, which is -2.31% below the current Price to Sales Ratio (P/S).
  • MEDINET Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 17.25.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
Tokyo Stock Exchange: 2370.T

MEDINET Co., Ltd.

CEO Kanenao Kubushiro
IPO Date Oct. 8, 2003
Location Japan
Headquarters TRC Center Building
Employees 92
Sector Health Care
Industries
Description

MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. Further, the company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.

Similar companies

2134.T

Kitahama Capital Partners Co.,Ltd.

USD 0.11

-0.18%

2160.T

GNI Group Ltd.

USD 19.77

1.11%

4564.T

OncoTherapy Science, Inc.

USD 0.15

4.16%

4591.T

Ribomic Inc.

USD 0.54

-2.45%

StockViz Staff

January 15, 2025

Any question? Send us an email